Sixth Street, KKR Fund BridgeBio With $1 Billion Equity

Sixth Street Partners and KKR & Co. have committed to providing $1 billion in preferred equity financing to BridgeBio Pharma Inc. This significant funding injection is intended to bolster BridgeBio's efforts in advancing its pipeline of novel therapeutics. The agreement was confirmed by individuals familiar with the transaction.

BridgeBio Pharma, a clinical-stage biopharmaceutical company, focuses on developing medicines for genetic diseases. The company's portfolio includes programs targeting conditions such as cystic fibrosis, achromatopsia, and various rare genetic disorders. The substantial capital infusion from Sixth Street and KKR is expected to accelerate the development and potential commercialization of these promising drug candidates.

This financial arrangement underscores the growing investor confidence in BridgeBio's scientific approach and its potential to address unmet medical needs. The preferred equity structure typically offers lenders a degree of security while providing the company with necessary capital without immediate dilution of common stock. The specifics of the deal, including the terms of the preferred equity, have not been publicly disclosed.

Sixth Street Partners is a global investment firm with a diversified portfolio across various sectors, including life sciences. KKR & Co. is a leading global investment firm with a long history of investing in healthcare and biotechnology companies. Their participation in this funding round highlights the strategic importance of BridgeBio's therapeutic areas and its potential for future growth.